CypA/TAF15/STAT5A/miR-514a-3p feedback loop drives ovarian cancer metastasis
- PMID: 39402372
- DOI: 10.1038/s41388-024-03188-w
CypA/TAF15/STAT5A/miR-514a-3p feedback loop drives ovarian cancer metastasis
Abstract
Cyclophilin A (CypA) is a peptidyl-prolyl isomerase that participates in multiple cancer events, but the molecular mechanisms of abnormal expression and regulation of CypA in ovarian cancer (OC) have never been considered. This study identifies CypA as a key driver of epithelial-mesenchymal transition (EMT) in ovarian cancer and explores the mechanisms that underly this process. We show that CypA is upregulated in tissues and serum of ovarian cancer patients and that CypA overexpression correlates with poor prognosis. CypA facilitates tumor growth and metastasis in vivo in subcutaneous tumor xenograft and abdominal metastatic models, and in vitro studies suggest a mechanism, showing that CypA accelerates ovarian cancer cell epithelial-mesenchymal transition by activating a PI3K/AKT signaling pathway. Mechanistic studies showed that STAT5A binds pri-miR-514a-3p and inhibits its activity, whereas miR-514a-3p directly binds to the 3'-UTR of CypA to suppress its expression, resulting in STAT5A promoting the expression of CypA, forming the STAT5A/miR-514a-3p/CypA axis. Furthermore, immunoprecipitates and mass spectrometry analysis identifies a CypA interaction with TAF15 that stabilizes TAF15 by suppressing its proteasome degradation and promotes its entry into the nucleus. While STAT5A is positively regulated by TAF15. Our findings identify a novel feedback loop for CypA that drives EMT and ovarian tumor growth and metastasis via a TAF15/STAT5A/miR-514a-3p pathway in ovarian cancer and facilitates the release of CypA into the extracellular, which provides a promising therapeutic target for OC treatment and a diagnostic biomarker.
© 2024. The Author(s), under exclusive licence to Springer Nature Limited.
Conflict of interest statement
Competing interests: The authors declare no competing interests. Ethical approval: The informed consent was obtained from patients and the study was approved by the Medical Ethics Committee of the Affiliated Hospital of Xuzhou Medical University (XYFY2022-KL439-01). All the research was performed in accordance with government policies and the Helsinki declaration. The animal experiments were approved by the Institutional Animal Care and Use Committee of Xuzhou Medical University (202005A009).
Similar articles
-
FoxP3-miR-150-5p/3p suppresses ovarian tumorigenesis via an IGF1R/IRS1 pathway feedback loop.Cell Death Dis. 2021 Mar 15;12(3):275. doi: 10.1038/s41419-021-03554-6. Cell Death Dis. 2021. PMID: 33723215 Free PMC article.
-
Non-canonical signaling pathway of SNAI2 induces EMT in ovarian cancer cells by suppressing miR-222-3p transcription and upregulating PDCD10.Theranostics. 2020 Apr 27;10(13):5895-5913. doi: 10.7150/thno.43198. eCollection 2020. Theranostics. 2020. PMID: 32483426 Free PMC article.
-
lncRNA AC005224.4/miR-140-3p/SNAI2 regulating axis facilitates the invasion and metastasis of ovarian cancer through epithelial-mesenchymal transition.Chin Med J (Engl). 2023 May 5;136(9):1098-1110. doi: 10.1097/CM9.0000000000002201. Chin Med J (Engl). 2023. PMID: 36939239 Free PMC article.
-
Overexpression of Long Noncoding RNA H19 Downregulates miR-140-5p and Activates PI3K/AKT Signaling Pathway to Promote Invasion, Migration and Epithelial-Mesenchymal Transition of Ovarian Cancer Cells.Biomed Res Int. 2021 Jun 21;2021:6619730. doi: 10.1155/2021/6619730. eCollection 2021. Biomed Res Int. 2021. PMID: 34250088 Free PMC article.
-
MicroRNA-338-3p suppresses ovarian cancer cells growth and metastasis: implication of Wnt/catenin beta and MEK/ERK signaling pathways.J Exp Clin Cancer Res. 2019 Dec 16;38(1):494. doi: 10.1186/s13046-019-1494-3. J Exp Clin Cancer Res. 2019. Retraction in: J Exp Clin Cancer Res. 2024 Feb 15;43(1):48. doi: 10.1186/s13046-024-02978-0. PMID: 31842953 Free PMC article. Retracted.
Cited by
-
Nuclear receptor coactive 4-mediated ferritinophagy: a key role of heavy metals toxicity.Arch Toxicol. 2025 Apr;99(4):1257-1270. doi: 10.1007/s00204-025-03963-y. Epub 2025 Feb 10. Arch Toxicol. 2025. PMID: 39928088 Review.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous